Angi Inc vs Citius Pharmaceuticals Inc — how do they compare? Angi Inc trades at $4.37 (market cap $182.30M), while Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M). The key difference: Angi Inc is far larger — about 9.1× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, Angi Inc nearer its low. Which is the better fit depends on your goals.
| ANGI | CTXR | |
|---|---|---|
Market Cap | $182.30M | $20.01M |
Sector | Media | Health |
52-Week High | $18.46 | $1.82 |
52-Week Low | $4.49 | $0.48 |
Enterprise Value | $392.07M | $16.23M |
Signals from Pluang's Aura AI — not financial advice
ANGI trades at $4.41, down 3.92% with bearish technical signals and mixed fundamentals. Revenue declined to $1.03B in 2025, though net income improved to $44M. The stock appears undervalued with P/E of 14.81 and P/S of 0.19, but faces challenges with declining revenue trends and negative 2026 projections. Recent Q2 2026 earnings missed expectations with a $5.70 EPS loss versus $0.13 expected, while multiple law firms investigate potential securities violations.
Outlook remains challenging with revenue projected to decline to $993M in 2026 and net loss of $222M. The 59% upside to consensus price target of $7.00 offers potential reward, but risks include accelerating pro user churn, negative cash flow trends, and ongoing securities investigations. Analyst sentiment is cautious with 64% hold ratings amid fundamental deterioration.
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Trailing returns across standard periods
Latest headlines on both assets
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →